# Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2

> **NCT02024009** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 159 (actual)

## Conditions studied

- Pancreatic Neoplasms (Locally Advanced Non-metastatic)

## Interventions

- **DRUG:** nab-paclitaxel
- **RADIATION:** 60Gy in 30#
- **RADIATION:** 50.4Gy in 28#
- **DRUG:** Nelfinavir
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02024009
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2021-06-23
- **Final completion:** 2021-06-23
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2024-07-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02024009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02024009, "Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02024009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*